We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Excess Inflammasome Activity Leads to Formation of Atherosclerosis

By LabMedica International staff writers
Posted on 03 Jul 2018
Print article
Image: Atherosclerotic lesions appear in red in this photomicrograph of a mouse aorta (Photo courtesy of Cedars-Sinai Medical Center).
Image: Atherosclerotic lesions appear in red in this photomicrograph of a mouse aorta (Photo courtesy of Cedars-Sinai Medical Center).
Results presented in a recently published paper explain how chronic inflammation of the arterial walls progresses to arteriosclerosis, a disorder characterized by clogged arteries and increased risk of heart attack and stroke.

Pathogen burden, such as infection by the bacterium Chlamydia pneumoniae (C.pn) accelerates formation of atherosclerosis, but the mechanisms have remained unresolved. As it was known that activation of the NLRP3 inflammasome was linked to atherogenesis, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) examined whether infection stimulated NLRP3 in promoting atherosclerosis.

NALP3 protein, which is encoded by the NLRP3 gene, is expressed predominantly in macrophages and as a component of the inflammasome detects products of damaged cells such as extracellular ATP and crystalline uric acid. Activated NALP3 in turn triggers an immune response. Mutations in the NLRP3 gene are associated with a number of organ specific autoimmune diseases.

The inflammasome is a multiprotein oligomer responsible for the activation of inflammatory responses. It promotes the maturation and secretion of pro-inflammatory cytokines interleukin-1beta (IL-1beta) and interleukin 18 (IL-18). The secretion of these cytokines results in pyroptosis, a form of programmed pro-inflammatory cell death distinct from apoptosis. In the case of dysregulation of the inflammasome, an assortment of major diseases may arise. It is expressed in myeloid cells and is a component of the innate immune system.

For the current study, the investigators worked with cultured human cells and with mice infected by C.pn. Results published in the June 21, 2018, online edition of the journal Cell Metabolism revealed that C.pn potentiated hyperlipidemia-induced inflammasome activity in cultured macrophages and in foam cells in atherosclerotic lesions of mice lacking the LDL (low-density lipoprotein) receptor. C.pn-induced acceleration of atherosclerosis was significantly dependent on NLRP3 and caspase-1.

Mature IL-1beta and cholesterol were found to compete for access to the same transporter for export from macrophages.

"We have known for decades that atherosclerosis is a disease of chronic inflammation that ultimately results in the scarring of arteries and tissue damage," said senior author Dr. Moshe Arditi, professor of pediatrics and biomedical sciences at Cedars-Sinai Medical Center. "But the ongoing stimulus for this inflammation has been unclear. The Cedars-Sinai study raises the possibility that by using drugs to block the initial production of interleukin-1beta, rather than just neutralizing it, a stronger positive effect could be obtained for these patients."

Related Links:
Cedars-Sinai Medical Center

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.